References
- Federal Motor Carrier Safety Administration. What tests are required and when does testing occur? Washington, D.C.: United States Department of Transportation; [updated July 22, 2021. cited 2022 May 17]. Available from: https://www.fmcsa.dot.gov/regulations/drug-alcohol-testing/what-tests-are-required-and-when-does-testing-occur.
- National Conference of State Legislatures. Drugged driving: marijuana-impaired driving Washington, D.C.2022. [cited 2022 May 17]. Available from: https://www.ncsl.org/research/transportation/drugged-driving-overview.aspx.
- McCartney D, Arkell TR, Irwin C, et al. Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175–193.
- Lowe RH, Abraham TT, Darwin WD, et al. Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009;105(1-2):24–32.
- Peng YW, Desapriya E, Chan H, et al. Residual blood THC levels in frequent cannabis users after over four hours of abstinence: a systematic review. Drug Alcohol Depend. 2020;216:108177.
- Schwope DM, Bosker WM, Ramaekers JG, et al. Psychomotor performance, subjective and physiological effects and whole blood Δ9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol. 2012;36(6):405–412.
- Daldrup T, Meininger I. Begutachtung der Fahrtüchtigkeit unter Cannabis im Straßenverkehr [Assessment of unfitness to drive under the influence of cannabis in the legal system]. In: Berghaus G, Krüger HP, editors. Cannabis im Straßenverkehr [Cannabis on the Road]: Stuttgart: Jena Lübeck Ulm; 1998. p. 181–204.
- Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev. 2018;93:1–25.
- Brooks-Russell A, Brown T, Friedman K, et al. Simulated driving performance among daily and occasional cannabis users. Accid Anal Prev. 2021;160:106326.
- Schwope DM, Scheidweiler KB, Huestis MA. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry. Anal Bioanal Chem. 2011;401(4):1273–1283.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.
- Newmeyer MN, Swortwood MJ, Barnes AJ, et al. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem. 2016;62(12):1579–1592.
- Odell MS, Frei MY, Gerostamoulos D, et al. Residual cannabis levels in blood, urine, and oral fluid following heavy cannabis use. Forensic Sci Int. 2015;249:173–180.
- Colorado Department of Public Health and Environment. 2020 BRFSS Summary Table Denver, CO 2020. [cited 2022 June 27]. Available from https://cdphe.colorado.gov/center-for-health-and-environmental-data/survey-research/behavioral-risk-factor-surveillance-system.
- Canada. Canadian Cannabis Survey 2021: summary Canada2021 updated December 23, 2021. [cited 2022 May 17]. Available from https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2021-summary.html.
- D’Orazio AL, Mohr ALA, Logan BK. 2020 Toxicology Laboratory Survey. Willow Grove, PA: Center for Forensic Science Research and Education; 2020. [available at: https://www.cfsre.org/images/content/research/toxicology/Survey_Report_Final.pdf. ]
- Ramaekers JG, Kauert G, van Ruitenbeek P, et al. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31(10):2296–2303.
- Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology (Berl). 2019;236(9):2713–2724.
- Desrosiers NA, Himes SK, Scheidweiler KB, et al. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60(4):631–643.
- Schwope DM, Karschner EL, Gorelick DA, et al. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem. 2011;57(10):1406–1414.
- Scheidweiler KB, Himes SK, Desrosiers NA, et al. In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis. Forensic Toxicol. 2016;34(1):179–185.